HYDERABAD, India, June 23, 2026 /PRNewswire/ -- According to the latest report by Mordor Intelligence, the ophthalmic drugs market size was valued at USD 40.58 billion in 2026 and is projected to expand to USD 60.29 billion by 2031. The market is expected to register a CAGR of 8.24% during the forecast period from 2026 to 2031, supported by the increasing prevalence of eye diseases, growing aging population, and continued advancements in ocular drug development. The market is benefiting from rising awareness regarding vision care, expanding access to ophthalmic treatments, and increasing investments in innovative therapies for chronic and age-related eye conditions.
The ophthalmic drugs market continues to evolve as healthcare systems worldwide focus on addressing the growing burden of vision impairment and blindness. Conditions such as glaucoma, dry eye disease, retinal disorders, allergic conjunctivitis, and age-related macular degeneration are becoming increasingly common, creating sustained demand for effective therapeutic solutions. Pharmaceutical companies are actively developing advanced treatment options that improve patient outcomes while enhancing convenience and treatment adherence.
Market expansion is further supported by demographic trends and changing healthcare needs. The growing elderly population remains particularly vulnerable to ophthalmic conditions, increasing the need for long-term disease management and specialized therapies. At the same time, rising screen exposure, urban lifestyles, and environmental factors are contributing to higher incidence rates of eye-related disorders among broader patient populations.
Ophthalmic Drugs Market Share by Region
North America represents a significant share of the ophthalmic drugs market, supported by advanced healthcare infrastructure, high awareness regarding eye health, strong pharmaceutical research capabilities, and early adoption of innovative therapies.
Europe holds a notable position in the market, driven by increasing prevalence of age-related eye diseases, growing healthcare investments, and expanding access to specialized ophthalmic care services.
Asia-Pacific is emerging as a high-growth region due to rising healthcare expenditure, growing aging populations, increasing awareness regarding eye health, and expanding access to ophthalmic treatments across countries such as China, India, and Japan.
Soumya Goud, Senior Research Manager, Mordor Intelligence, says, "The ophthalmic drugs market continues to reflect evolving treatment approaches and growing clinical demand for advanced ocular therapies. Mordor Intelligence applies a structured research framework supported by cross-validated data and consistent analytical methodologies, enabling decision-makers to evaluate market developments with greater confidence and clarity."
Ophthalmic Drugs Market Trends & Forecast
Growing Adoption of Advanced Ocular Therapeutics
Healthcare providers are increasingly utilizing innovative ophthalmic drugs, including biologics and targeted therapies, to address complex eye disorders and improve long-term patient outcomes.
Increasing Focus on Drug Delivery Innovation
Manufacturers are investing in sustained-release formulations and advanced drug delivery technologies designed to improve treatment adherence and reduce administration frequency.
Ophthalmic Drugs Market Segmentation Overview
Drug Class
- Anti-glaucoma Drugs
- Dry Eye Drugs
- Anti-inflammatory Drugs
- Anti-infective Drugs
- Retinal Disorder Drugs
- Anti-allergy Drugs
- Combination Therapies
Indication
- Glaucoma
- Dry Eye Syndrome
- Retinal Disorders
- Allergic Conjunctivitis
- Ocular Infections & Inflammation
- Others (Presbyopia, Post-surgical, Rare Diseases)
Dosage Form
- Eye Drops
- Ointments & Gels
- Capsules & Tablets
- Implants & Inserts
- Sprays & Nasal Delivery
Product Type
- Prescription Drugs
- OTC Drugs
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report:https://www.mordorintelligence.com/industry-reports/global-opthalmic-drugs-market?utm_source=prnewswire
Ophthalmic Drugs Market Competitive Outlook
The ophthalmic drugs market features global pharmaceutical companies, biotechnology firms, and specialty ophthalmology-focused organizations competing through innovation, product development, and strategic collaborations. Market participants are investing in biologics, novel drug delivery technologies, and next-generation ocular therapies to strengthen their market positions and address evolving patient needs. Product launches, clinical development programs, and research partnerships continue to shape competitive dynamics across the industry.
Major Companies in the Ophthalmic Drugs Market include:
- F. Hoffmann-La Roche AG
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- AbbVie Inc.
- Santen Pharmaceutical Co., Ltd.
Check out related reports published by Mordor Intelligence:
Cervical Dystonia Treatment Market Size - The cervical dystonia treatment market is projected to grow from USD 603.37 million in 2026 to USD 753.72 million by 2031, registering a CAGR of 4.55% during the forecast period. Growth is supported by increasing diagnosis rates of neurological movement disorders, rising awareness of available treatment options, and greater adoption of botulinum toxin therapies and supportive care approaches.
Dermatological Therapeutics Market Analysis - The dermatological therapeutics market is expected to expand from USD 54.06 billion in 2026 to USD 83.59 billion by 2031, at a CAGR of 9.12%. Market growth is driven by the increasing prevalence of skin disorders, growing demand for targeted treatment options, and rising healthcare spending focused on dermatology care and chronic skin disease management.
Acute Myeloid Leukemia Therapeutics Market Trends -The acute myeloid leukemia therapeutics market is estimated to grow from USD 3.18 billion in 2026 to USD 5.18 billion by 2031, registering a CAGR of 10.29% during the forecast period. Growth is fueled by increasing incidence of leukemia, expanding use of targeted and personalized therapies, and ongoing research efforts aimed at improving treatment outcomes for patients with acute myeloid leukemia.
Know more about Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/contact-us
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ophthalmic-drugs-market-outlook-20262031-over-8-cagr-projected-as-advancements-in-ocular-therapeutics-drive-growth-says-mordor-intelligence-302807785.html
